Clinical Trials Directory

Trials / Unknown

UnknownNCT02785575

Adjusted Calculation of Heparin and Protamin Dosing and Correlation With Postoperative Bleeding and Transfusions

The Impact of an Adjusted Calculation Model Regarding Heparin and Protamine Dosing on Bleeding and Transfusions After Cardiac Surgery Compared With Standard Dosing: A Randomized Single Blind Trial

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
200 (estimated)
Sponsor
Karolinska University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study will compare a novel calculation model (HeProCalc AB) with a standard weight-based and activated clotting time adjusted calculation for the dosing of Heparin and protamine and assess the impact on postoperative bleeding and blood transfusions after cardiac surgery.

Detailed description

During cardiac surgery with cardiopulmonary bypass (CPB), efficient anticoagulation is required in order to avoid microscopic clot formation or, in worst case, massive lift threatening thrombus formation. Heparin is by far the most common drug used to prevent blood from coagulating during CPB. Activated clotting time (ACT) is a point-of-care test of fibrin clotting time that has to be well prolonged to initiate safe CPB. Following weaning from CPB, heparin is reversed by protamine. Administration of excess doses of protamine may have a deleterious effect on coagulation and contribute to postoperative bleeding with need of blood transfusions. In connection with CPB management, heparin and protamin doses are commonly calculated using body weight and ACT. However, a new Heparin-Protamin-Calculation computer program (HeProCalc) has been developed to provide patient titrated dosing of both heparin and protamin. However, any benefits regarding postoperative bleeding and transfusions has not been thoroughly investigated.

Conditions

Interventions

TypeNameDescription
OTHERHeProCalc algorithmHeparin and protamine dosage calculated by the algorithm HeProCalc

Timeline

Start date
2016-04-01
Primary completion
2016-12-01
Completion
2018-02-01
First posted
2016-05-30
Last updated
2017-10-06

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT02785575. Inclusion in this directory is not an endorsement.